Navigation Links
OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be hosting an exhibition table at the 6th Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition will highlight a poster presentation providing preliminary results from their phase IV head and neck cancer and phase I breast cancer trials carried out in Europe using OncoSec's OMS ElectroChemotherapy™ treatment approach.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"We are pleased to highlight at this important scientific conference the extent of our clinical development activities of our OMS ElectroChemotherapy™ program and begin to share validating data from prior clinical trials that supports the merits of the therapy," said Punit Dhillon, president and CEO of OncoSec. "Our aim is to complete data analysis from the previous OMS ElectroChemotherapy™ programs and present this clinical data at applicable oncology and scientific meetings and seek a commercialization path for the product with the help of one or more industry partnerships from select geographic regions or globally."

Through its asset acquisition, OncoSec has accumulated a significant database of clinical data in a variety of tumor types using the OMS ElectroChemotherapy™ therapeutic approach.  To date OMS ElectroChemotherapy™ has been tested in several clinical trials ranging from Phase I through Phase IV conducted in 13 countries across over 50 sites.  Human data has been collected in over 400 patients with cancers ranging from basal and squamous cell carcinomas, melanoma, adenocarcinoma, Kaposi's sarcoma, pancreatic, hepatic, oral, and head and neck
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
(Date:6/18/2013)... , June 18, 2013  In a letter to ... , M.D., of Lake View, Iowa , ... receive annual influenza vaccine is neither scientifically justified nor ethically ... article in the summer issue of the Journal ... official statistics are correct, and an average of 36,000 patients ...
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... includes coverage of the Middle East ... Market Access Tracker analyzes the challenges and opportunities ... in four international regions comprising 24 countries. The ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3
... 18, 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced that it has ... clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety ... of cenderitide in patients with chronic heart failure. ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... demonstrated in an IRB approved, randomized, placebo controlled, double-blinded ... has an impact on allergic rhinitis, a clinical condition ...
Cached Medicine Technology:Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 2Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 3Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 4Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 2Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 3
(Date:6/19/2013)... 19, 2013 Indosoft Inc., developers ... for Asterisk, announced today the availability of ... enhancement offers improved options for extracting, consolidating and ... effective contact center management. , Large Asterisk based ... as it happens from the call center software. ...
(Date:6/19/2013)... BEACH, Florida (PRWEB) June 19, 2013 ... an emphasis upon crystal meth addiction treatment, helping men ... this powerful drug. , Crystal meth is a stimulant ... manufactured. The drug is most commonly smoked, but it ... It is commonly created in homemade labs using common ...
(Date:6/19/2013)... June 19, 2013 CoachingWebsites, ... for coaches, announced today its affiliation with ... will offer exclusive websites and marketing solutions and ... “This new partnership with Active Intelligence shows our ... to its fullest,” says Greer Van Dyck, Online ...
(Date:6/19/2013)... The US Drug Watchdog says, ... specifically designed to help a recipient of a DePuy Pinnacle ... elevated levels of cobalt, and chromium, because we believe this ... device is doing. In the event the cobalt, or chromium ... the person will need to consider, including possible revision surgery ...
(Date:6/19/2013)... 19, 2013 The Mesothelioma Victims ... Control of the 2500 to 3000 citizens, who will ... mesothelioma this year, about one third will be US ... diagnosed with this asbestos exposure form of cancer, or ... access to the nations most skilled mesothelioma compensation settlement ...
Breaking Medicine News(10 mins):Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2Health News:Crystal Meth Addiction Treatment and Crystal Meth Drug Rehab Announced by Recovery Associates 2Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2Health News:US Drug Watchdog Now Urges Recipients Of A DePuy Pinnacle All Metal Hip Implant To Call Them About A Vital Blood Test To See If Their Hip Implant Device Has Failed 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3
... the leading cause of visual impairment and blindness in ... people. ,The American Academy of Ophthalmology ... there are new treatments that can usually recover lost ... ,The Academy encourages those older than 50 ...
... men who become impotent after prostate cancer surgery may find ... the penis,// which assists in restoring the lost erectile function, ... findings came to light after a study of nearly 44 ... erectile function, following its loss after treatment for prostate cancer. ...
... caused by meningococcal infection and the disease spreads like wild ... of weeks in the late 1990s. Mortality rate in cases ... Patients also run a high risk of serious disability after ... each year 170,000 people around the world die of this ...
... breakfast was recalled from Singapore's markets as a precautionary ... that the product might be contaminated and cause botulism, ... were told to recall Earth's Best Organic 2 Apple ... from the Agri-Food and Veterinary Authority. ,The ...
... to a recent study published in February 21 Journal ... cancer// are at a higher risk of developing a ... for childhood cancer have resulted in a current overall ... shown that these survivors are specifically at a higher ...
... distress should be evaluated for primary ciliary dyskinesia, a ... fibrosis. ,According to Thomas Ferkol, M.D., ... that about 80 percent of patients with primary ciliary ... ,"The diagnosis of PCD requires a high ...
Cached Medicine News:Health News:Spring is Time for Age-Related Macular Degeneration (AMD) Awareness 2Health News:Survivors of Childhood Cancers at Higher Risk for Secondary Cancer 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: